HALEON PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 321 GBX | -0.90% |
|
-2.84% | +0.02% |
| May. 21 | Bernstein becomes more optimistic for consumer goods - Henkel upgraded | DP |
| May. 17 | UK's FTSE 100 Closes Lower Amid Inflation Focus | MT |
| Sales 2024 * | 11.45B 14.6B | Sales 2025 * | 11.93B 15.22B | Capitalization | 29.58B 37.73B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.46B 1.86B | Net income 2025 * | 1.69B 2.15B | EV / Sales 2024 * | 3.27 x |
| Net Debt 2024 * | 7.81B 9.97B | Net Debt 2025 * | 7.07B 9.02B | EV / Sales 2025 * | 3.07 x |
| P/E ratio 2024 * |
20.2
x | P/E ratio 2025 * |
17.6
x | Employees | 25,408 |
| Yield 2024 * |
1.9% | Yield 2025 * |
2.2% | Free-Float | 81.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Haleon plc
More press releases
| 1 day | +0.28% | ||
| 1 week | -2.29% | ||
| Current month | -4.59% | ||
| 1 month | -3.14% | ||
| 3 months | +3.17% | ||
| 6 months | -3.43% | ||
| Current year | +0.70% |
1 week
322.60
333.30
1 month
322.60371.20
Current year
308.37371.20
1 year
306.80371.20
3 years
241.17371.20
5 years
241.17371.20
10 years
241.17371.20
| Managers | Title | Age | Since |
|---|---|---|---|
Brian McNamara
CEO | Chief Executive Officer | 57 | 21-07-21 |
Tobias Hestler
DFI | Director of Finance/CFO | 52 | 21-11-30 |
Franck Riot
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bryan Supran
BRD | Director/Board Member | - | 22-07-17 |
Dame Cox
BRD | Director/Board Member | 64 | 22-07-17 |
Tracy Clarke
BRD | Director/Board Member | 57 | 22-07-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.35% | 142 M€ | +13.78% | - | |
| 0.99% | 11 M€ | +0.83% | - | |
| 0.94% | 5 M€ | +16.25% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-29 | 321.7 | -0.68% | 1 302 306 |
| 24-05-28 | 323.9 | +0.28% | 30,423,870 |
| 24-05-24 | 323 | -1.79% | 14,185,250 |
| 24-05-23 | 328.9 | -0.66% | 9,564,818 |
| 24-05-22 | 331.1 | -0.12% | 49,591,040 |
Delayed Quote London S.E., May 28, 2024 at 11:35 am EDT
More quotes
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows:
- oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.;
- Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.;
- medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.;
- respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.;
- vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
Pharmaceuticals
Calendar
2024-08-01
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.239
GBP
Average target price
3.62
GBP
Spread / Average Target
+11.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.70% | 37.8B | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +13.47% | 238B | |
| +7.35% | 204B | |
| -6.42% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B |
- Stock Market
- Equities
- HLN Stock
